|Bid||13.51 x 800|
|Ask||16.98 x 1000|
|Day's Range||13.56 - 14.30|
|52 Week Range||8.89 - 46.20|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MYOS CORP ("MYOS" or the "Company"), a research-based advanced nutrition company with divisions that address both Human Nutrition and Animal Health, announced today that it has been granted United States Patent #10,925,904 by the United States Patent and Trademark Office (USPTO). The new patent, titled "Methods and Compositions for Improving Skeletal Muscle Protein Fractional Synthetic Rate," protects advanced technologies related to improving skeletal muscle protein synthetic rate in older mammals through the administration of proprietary nutritional compositions such as MYOS' advanced nutrition product, Fortetropin®.
MedAvail Holdings, Inc. (Nasdaq: MDVL) ("MedAvail") a technology-enabled retail pharmacy company, today announced that the company will be participating in the upcoming Cowen 41st Annual Health Care Conference.
MedAvail Holdings, Inc. (Nasdaq: MDVL) ("MedAvail") a technology-enabled pharmacy company, today announced preliminary financial and operational results for the fourth quarter and full year 2020.